COMPOUND IQRESEARCH. TESTED. EXPLAINED.Scan a COA

PEPTIDE NEWS · SOURCE FIRST

The headline is the start of the review.

Timely analysis of peptide regulation, testing, and clinical evidence. Every article separates what a primary source establishes from what the internet turns it into.

Supply-chain watch7 min read

FDA updated its GLP-1 import alert. A COA is only the first layer.

The September 21 revision describes detention without physical examination, a Green List, and the manufacturing evidence FDA expects beyond a single certificate.

Read the analysis

MORE SOURCE-BACKED COVERAGE

The regulatory record, without the social-media distortion.

Regulatory watch

FDA warned five peptide sellers in one day. Here’s what the letters actually say.

The newest FDA letters focus on marketing claims and intended use—not laboratory proof that every cited vial was impure.

Read the analysis

THE NEWS STANDARD

Fast enough to matter. Careful enough to trust.

Compound IQ news follows the same evidence discipline used in our COA reviews.

01

Start with the primary record

FDA notices, trial registrations, labels, journal papers, and laboratory records come before commentary.

02

Separate different questions

Analytical quality, clinical evidence, and regulatory status are related—but they are not interchangeable.

03

Show what did not happen

Every story identifies the conclusions a source supports and the conclusions it does not.